UOC
GRTX

UBS O'Connor’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

UBS O'Connor’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-302,506
Closed -$52.9K – 629
2023
Q3 		$52.9K Sell
302,506
-268,000
-47% -$333K ﹤0.01% 485
2023
Q2 		$1.78M Sell
570,506
-143,025
-20% -$426K 0.04% 321
2023
Q1 		$1.83M Buy
+713,531
New +$1.47M 0.04% 338

Other funds holding GRTX

GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS O'Connor's GRTX Position: Q4 2023 in Review

UBS O'Connor sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q4 2023, closing a stake of 302,506 shares — an estimated $52.9K sold.

UBS O'Connor first reported a position in GRTX in Q1 2023 and held it in 3 quarters. The position peaked at $1.83M in Q1 2023. 37 funds tracked by Wall St. Rank hold GRTX as of Q4 2023.

  • UBS O'Connor reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 302,506 Galera Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $52.9K.
  • UBS O'Connor first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • UBS O'Connor's Galera Therapeutics, Inc. Common Stock position peaked at $1.83M in Q1 2023.
  • 37 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.